Levetiracetam Injection
Product Images NDC 0264-1509

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 0264-1509). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by B. Braun Medical Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure A (Levetiracetam In Sodium Chloride Injection 1)

An illustration labeled Figure A showing the top section of an intravenous Levetiracetam injection container with labeled ports: a set port and an additive port.*

FDA Label Image

Dl5009 Container Label (Levetiracetam In Sodium Chloride Injection 10)

Label for Levetiracetam 5 mg/mL intravenous injection in 0.82% sodium chloride, provided in a 100 mL single-dose dual port container. The label includes the NDC 0264-5009-90, instructions for intravenous infusion over 15 minutes, storage conditions at 20°C to 25°C, and manufacturer information for B. Braun Medical Inc., Bethlehem, PA, USA.*

FDA Label Image

Dl1009 Container Label (Levetiracetam In Sodium Chloride Injection 11)

Label for Levetiracetam 1,000 mg/100 mL (10 mg/mL) intravenous injection in 0.75% Sodium Chloride, presented as a 100 mL single-dose container. The label includes storage instructions, usage cautions, and manufacturer details from B. Braun Medical Inc., Bethlehem, PA.*

FDA Label Image

Dl1509 Container Label (Levetiracetam In Sodium Chloride Injection 12)

Label for Levetiracetam 1,500 mg/100 mL (15 mg/mL) injection in 0.54% Sodium Chloride for intravenous infusion by B. Braun Medical Inc. The packaging is a 100 mL single-dose dual port container. The label includes storage instructions, usage cautions, and contact information for the manufacturer.*

FDA Label Image

Dl5009 Folding Carton (Levetiracetam In Sodium Chloride Injection 13)

Packaging label for Levetiracetam 5 mg/mL Injection in 0.82% Sodium Chloride, 100 mL fill, from B. Braun Medical Inc. The label includes dosage instructions, storage recommendations, and cautions, stating it is for intravenous infusion only and contains no natural rubber latex, PVC, or DEHP in the closure.*

FDA Label Image

Dl1009 Folding Carton (Levetiracetam In Sodium Chloride Injection 14)

Packaging label for Levetiracetam 10 mg/mL Injection in 0.75% Sodium Chloride by B. Braun Medical Inc. The label indicates a 100 mL fill PAB container with 1,000 mg of levetiracetam per 100 mL. It is for intravenous infusion only, single-dose use, and includes storage and usage instructions along with the labeler contact details.*

FDA Label Image

Dl1509 Folding Carton (Levetiracetam In Sodium Chloride Injection 15)

Packaging label for Levetiracetam injection 15 mg/mL in 0.54% Sodium Chloride by B. Braun Medical Inc. The label is for a single-dose 100 mL fill PAB container containing 1,500 mg per 100 mL. It includes instructions for intravenous infusion only, caution against using plastic containers in series, and recommended storage at 20° to 25°C. The label features the B. Braun logo and contact information.*

FDA Label Image

Figure B (Levetiracetam In Sodium Chloride Injection 2)

Illustration labeled Figure B showing a hand lifting the flip cap of a vial stopper, with an arrow indicating the lifting motion. This instructional diagram is related to the preparation or access of a vial, potentially for Levetiracetam injection by B. Braun Medical Inc.*

FDA Label Image

Figure C (Levetiracetam In Sodium Chloride Injection 3)

Illustration showing Step 1 and Step 2 of accessing the additive port on a B. Braun Medical Inc. Levetiracetam injection container. Step 1 instructs to lift a protective tab, and Step 2 instructs to peel off the tab towards the additive port, revealing the access point.*

FDA Label Image

Figure D (Levetiracetam In Sodium Chloride Injection 4)

An illustration labeled Figure D showing two hands connecting a dual-port adapter to a B. Braun Levetiracetam injection bag. The bag is marked with the B. Braun logo and an "ADD" label near the ports, indicating the preparation step for intravenous administration.*

FDA Label Image

Levetiracetam Structural Formula (Levetiracetam In Sodium Chloride Injection 5)

Chemical structure of Levetiracetam, showing its molecular formula with a five-membered ring containing oxygen and nitrogen atoms, and attached ethyl, hydrogen, and amide groups.*

FDA Label Image

Figure 1 (Levetiracetam In Sodium Chloride Injection 6)

A bar chart showing the percentage of patients for three groups: Placebo (7.4%, N=95), Levetiracetam 1000 mg/day (37.1%, N=97), and Levetiracetam 3000 mg/day (39.6%, N=101). Asterisks indicate statistically significant differences versus placebo.*

FDA Label Image

Figure 2 (Levetiracetam In Sodium Chloride Injection 7)

A bar chart showing the percentage of patients in three groups: placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%). Each bar is labeled with sample size and asterisk indicating statistical significance versus placebo. The y-axis is percentage of patients from 0% to 45%.*

FDA Label Image

Figure 7 (Levetiracetam In Sodium Chloride Injection 8)

A bar graph comparing the percentage of patients between two groups: placebo (N=104) and Levetiracetam 3000 mg/day (N=180). The graph shows approximately 14.4% for placebo and 39.4% for Levetiracetam, with a note indicating statistical significance versus placebo.*

FDA Label Image

Figure 8 (Levetiracetam In Sodium Chloride Injection 9)

A bar graph comparing the percentage of patients between Placebo (N=84) and Levetiracetam (N=79). The graph shows 45.2% for Placebo and 72.2% for Levetiracetam, with a note indicating statistical significance versus placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.